Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced Opexa has been named one of the “Top Projects to Watch” in advanced therapeutics by Elsevier Business Intelligence. As part of this recognition, Neil K. Warma, Opexa’s President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 18-20, 2013, at the Hyatt Regency Boston. Mr. Warma will present on Tuesday, November 19 at 2:55 p.m. E.S.T.
“Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer,” said David Cassak, Vice President, Content, Elsevier Business Intelligence. “Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), and potential for new opportunities beyond initial indications and corporate stability.”
“We are pleased to be recognized as one of the Top Projects to Watch in advanced therapies by such a distinguished group,” stated Mr. Warma. "This honor is a testament to Opexa’s leading position in the field of Precision Immunotherapy™, the potential Tcelna ® has to address the severe unmet medical need of the Secondary Progressive MS population, and the potential our T-cell platform has to address additional autoimmune disease indications.”
About OpexaOpexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna ®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. About Elsevier Business Intelligence Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis.